125459 -

: Evaluating whether the viral vector or therapeutic gene could unintentionally be passed on to future generations.

This document outlines the essential safety and efficacy data that developers must generate during the "non-clinical" (animal or lab) phase to justify moving into human subjects.

: Checking if the patient might "shed" or spread the virus/vector through secretions. 125459

The number most commonly refers to a specific scientific guideline established by the European Medicines Agency (EMA) regarding the development of Gene Therapy Medicinal Products (GTMPs) .

The guideline, officially titled , provides a framework for non-clinical studies required before a gene therapy can be used in human clinical trials. Guide to EMA Guideline 125459 : Evaluating whether the viral vector or therapeutic

: Determining where the therapeutic gene goes in the body and how long it persists in both target and non-target cells.

: Defining scientific principles for non-clinical studies specifically for gene therapies, which differ significantly from conventional pharmaceuticals. Key Safety Requirements : The number most commonly refers to a specific

: Characterizing potential immune responses to the viral vector or the new protein produced by the therapy.